QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 发表日期：2018    专题：西安交通大学    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China 期刊论文 ASIAN JOURNAL OF ANDROLOGY, 2018, 卷号: 20, 页码: 173-177 作者:  Wu, Kai-Jie;  Pei, Xin-Qi;  Tian, Ge;  Wu, Da-Peng;  Fan, Jin-Hai 收藏  |  浏览/下载：4/0  |  提交时间：2019/11/19 prostate-specific antigen  time to nadir  survival  castration-resistant prostate cancer  chemotherapy  docetaxel   PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Evidence from patients in Northwestern China 期刊论文 Asian Journal of Andrology, 2018, 卷号: 20, 页码: 173-177 作者:  Wu, Kai-Jie;  Pei, Xin-Qi;  Tian, Ge;  Wu, Da-Peng;  Fan, Jin-Hai 收藏  |  浏览/下载：3/0  |  提交时间：2019/11/26 Castration-resistant prostate cancer  Chemotherapy  Docetaxel  Prostate-specific antigen  Survival  Time to nadir   PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy 期刊论文 THERANOSTICS, 2018, 卷号: 8, 页码: 109-123 作者:  Zeng, Jin;  Liu, Wei;  Fan, Yi-Zeng;  He, Da-Lin;  Li, Lei 收藏  |  浏览/下载：3/0  |  提交时间：2019/11/26 PrLZ  LKB1  Prostate cancer  Docetaxel  Autophagy   The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis 期刊论文 ONCOTARGET, 2018, 卷号: 9, 页码: 4239-4248 作者:  Huang, Guanghong;  Sun, Xin;  Liu, Dapeng;  Zhang, Yunfeng;  Zhang, Boxiang 收藏  |  浏览/下载：3/0  |  提交时间：2019/11/26 NSCLC  meta-analysis  PD-1/PD-L1  Immune checkpoint inhibitor